New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
06:33 EDTALXNAlexion raises FY14 EPS view to $4.37-$4.47 from $3.70-$3.80, consensus $3.89
Raises FY14 net product revenue guidance to $2.15B-$2.17B from $2B-$2.02B, consensus $2.03B.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
17:03 EDTALXNOn The Fly: Top stock stories for Wednesday
Subscribe for More Information
15:11 EDTALXNAlexion weakness a buying opportunity, says Cowen
Cowen says Alexion (ALXN) remains a top pick and shares should be bought aggressively on weakness. The firm said the Synageva (GEVA) acquistion further expands Alexion's metabolic franchises and brings in a late stage blockbuster product candidate Kanuma, an enzyme replacement therapy for LAL-D, with U.S. and E.U. approvals.
13:28 EDTALXNOn The Fly: Top stock stories at midday
Subscribe for More Information
11:02 EDTALXNSynageva acquisition a good deal for Alexion, says Piper Jaffray
Subscribe for More Information
09:16 EDTALXNOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTALXNAlexion to host conference call
Subscribe for More Information
08:07 EDTALXNBioMarin up 4% to $118 after Synageva takeout
Subscribe for More Information
07:57 EDTALXNSynageva volatility flat into Alexion acquiring for $230 per share
Subscribe for More Information
07:38 EDTALXNAlexion volatility flat into acquiring Synageva for $230 per share
Subscribe for More Information
07:22 EDTALXNDeutsche Bank to hold a conference
40th Annual Health Care Conference is being held in Boston on May 6-7 with webcasted company presentations to begin on May 6 at 8 am; not all company presentations may be webcasted. Webcast Link
06:45 EDTALXNAlexion agrees to acquire Synageva in transaction valued at $8.4B net of cash
Subscribe for More Information
06:43 EDTALXNAlexion agrees to acquire Synageva in transaction valued at $8.4B net of cash
Subscribe for More Information
May 5, 2015
16:50 EDTALXNAlexion says eculizumab trial efficacy endpoint occurred in 18.8% of patients
Subscribe for More Information
07:57 EDTALXNDeutsche sees AbbVie, BioMarin outperforming near-term
Deutsche Bank analyst Robyn Karnauskas expects shares of AbbVie (ABBV) and BioMarin (BMRN) to outperform in the near-term following recent weakness in the biotech sector. On AbbVie, Karnauskas thinks data readouts in 2015 could add $15-$25 per share over time. For BioMarin, the analyst thinks only three of the five pipeline readouts need to work in 2015. The company's takeout valuation could be up to $217 per share if data for BMN-111 for Achondroplasia, Drisapsrsen for Duchenne muscular dystrophy and BMN 270 for hemophilia are positive, Karnauskas believes. The analyst also recommends buying Celgene (CELG) and Alexion (ALXN) on any weakness for upside in the second half of 2015.
May 4, 2015
07:26 EDTALXNWorldwide Business Research to hold a conference
BioNetwork East 2015 Partnering Conference is being held in Miami on May 4-6.
April 27, 2015
08:26 EDTALXNAlexion coverage assumed with an Outperform at Oppenheimer
Subscribe for More Information
April 24, 2015
08:33 EDTALXNAlexion has reached attractive entry point, says SunTrust
Subscribe for More Information
April 23, 2015
11:23 EDTALXNAlexion weakness a buying opportunity, says Cowen
06:41 EDTALXNAlexion backs FY15 non-GAAP EPS view $5.60-$5.80, consensus $5.87
Subscribe for More Information
06:39 EDTALXNAlexion reports Q1 non-GAAP EPS $1.28, consensus $1.33
Reports Q1 revenue $600.3M, consensus $591.38M. Reports Q1 net product sales of Soliris $600.3M vs. $566.6M a year ago.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use